BATF2 and gastric cancer: One hundred patients receiving ICB after the diagnosis of advanced gastric cancer (54 responders and 46 non-responders) were separated according to the IHC staining score of CD8, PD-L1, MYB, BATF2 and CD36: CD8+PDL1 model favorable group (CD8+ PD-L1+, n = 62) and others (n = 38); IHC model favorable group (MYB+ BATF2+ CD36-, n = 52), and others (n = 48); combined model favorable group (CD8+ PD-L1+ MYB+ BATF2+ CD36-, n = 39) and others (n = 61).